Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 984 entries
View as:

Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.

Phase: N/A Priority: Normal
NCT ID: NCT00744627 Org: User:
Start: 09/30/08 End: 07/31/09 Due: 07/31/10

A Study on Estimated Risks of Certain Adverse Events in Adults With Von Willebrand Disease (VWD) Treated With Veyvondi

Phase: N/A Priority: Normal
NCT ID: NCT05265078 Org: User:
Start: 06/08/22 End: 04/06/23 Due: 04/06/24

Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria

Phase: N/A Priority: Normal
NCT ID: NCT02410499 Org: User:
Start: 05/20/15 End: 11/17/15 Due: 11/17/16

A Phase 2/3 Study of TVP-1012 at 0.5 mg or 1 mg in Levodopa Treated Parkinson's Disease Participants

Phase: N/A Priority: Normal
NCT ID: NCT02337738 Org: User:
Start: 01/27/15 End: 09/17/16 Due: 09/17/17

A Study in Teenagers and Adults With Hereditary Angioedema (HAE) Type I or Type II Who Use Lanadelumab as Long-Term Prophylaxis

Phase: N/A Priority: Normal
NCT ID: NCT04861090 Org: User:
Start: 09/15/21 End: 06/30/22 Due: 06/30/23

Effect of Antacid on Bioavailability of Febuxostat After Administration of a Febuxostat 80 mg Extended-Release Capsule

Phase: N/A Priority: Normal
NCT ID: NCT02382640 Org: User:
Start: 03/31/15 End: 05/31/15 Due: 05/31/16

Food Effect Study of Febuxostat XR in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT02374164 Org: User:
Start: 02/28/15 End: 04/30/15 Due: 04/30/16

Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study

Phase: N/A Priority: Normal
NCT ID: NCT02760615 Org: User:
Start: 11/01/16 End: 08/01/20 Due: 08/01/21

Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia

Phase: N/A Priority: Normal
NCT ID: NCT01350999 Org: User:
Start: 11/30/09 End: 01/31/11 Due: 01/31/12

A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT03942263 Org: User:
Start: 05/31/19 End: 12/08/22 Due: 12/08/23

Efficacy of SYR-472 in Subjects With Type 2 Diabetes Mellitus

Phase: N/A Priority: Normal
NCT ID: NCT00653185 Org: User:
Start: 05/31/07 End: 03/31/08 Due: 03/31/09

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-438 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT02123953 Org: User:
Start: 10/31/08 End: 03/31/09 Due: 03/31/10

Safety and Efficacy of Peginesatide Injection for the Maintenance of Anemia in Chronic Renal Failure Participants Who Are on Hemodialysis or Do Not Require Dialysis and Previously Treated With Darbepoetin Alfa.

Phase: N/A Priority: Normal
NCT ID: NCT00752609 Org: User:
Start: 09/30/08 End: 12/31/09 Due: 12/31/10

Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease

Phase: N/A Priority: Normal
NCT ID: NCT01132638 Org: User:
Start: 08/31/11 End: 06/30/12 Due: 06/30/13

Efficacy and Safety of Alogliptin Used in Combination With Sulfonylurea in Participants With Type 2 Diabetes in Japan

Phase: N/A Priority: Normal
NCT ID: NCT01318083 Org: User:
Start: 08/31/08 End: 04/30/09 Due: 04/30/10

Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection

Phase: N/A Priority: Normal
NCT ID: NCT03050359 Org: User:
Start: 04/05/17 End: 07/19/19 Due: 07/19/20

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT05743465 Org: User:
Start: 10/06/21 End: 11/30/22 Due: 11/30/23

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Phase: N/A Priority: Normal
NCT ID: NCT06441578 Org: User:
Start: 05/30/24 End: 09/30/32 Due: 09/30/33

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06076642 Org: User:
Start: 11/04/24 End: 01/15/29 Due: 01/15/30

Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT02049814 Org: User:
Start: 05/09/14 End: 06/28/16 Due: 06/28/17

A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition

Phase: N/A Priority: Normal
NCT ID: NCT06963827 Org: User:
Start: 08/15/25 End: 01/14/30 Due: 01/14/31

A Study of Maribavir in Chinese Adults With Cytomegalovirus (CMV) Infections

Phase: N/A Priority: Normal
NCT ID: NCT06439342 Org: User:
Start: 12/16/24 End: 12/31/26 Due: 12/31/27

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Phase: N/A Priority: Normal
NCT ID: NCT04530123 Org: User:
Start: 06/23/22 End: 01/19/26 Due: 01/19/27

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT02791438 Org: User:
Start: 08/18/16 End: 06/04/19 Due: 06/04/20

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01549964 Org: User:
Start: 04/30/12 End: 03/31/14 Due: 03/31/15